Table 2.
Multivariable analysis for DFS and OS in 227 AML patients who received standard intensive chemotherapy
| DFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | |||||||
| Variable | HR | Lower | Upper | P | HR | Lower | Upper | P |
| Age* | 1.007 | 0.995 | 1.019 | 0.253 | 1.030 | 1.014 | 1.047 | < 0.001 |
| WBC* | 1.004 | 1.002 | 1.007 | 0.001 | 1.005 | 1.001 | 1.008 | 0.012 |
| Karyotype† | 1.610 | 1.201 | 2.160 | 0.001 | 1.706 | 1.158 | 2.513 | 0.007 |
| NPM1/FLT3-ITD‡ | 0.601 | 0.332 | 1.089 | 0.093 | 0.895 | 0.443 | 1.808 | 0.757 |
| CEBPAdouble | 0.598 | 0.286 | 1.252 | 0.173 | 0.451 | 0.137 | 1.488 | 0.191 |
| RUNX1 | 1.532 | 0.875 | 2.683 | 0.136 | 1.432 | 0.726 | 2.821 | 0.300 |
| MLL-PTD | 2.706 | 1.263 | 5.799 | 0.010 | 2.882 | 1.077 | 7.710 | 0.035 |
| TP53 | 1.918 | 0.697 | 5.283 | 0.207 | 3.030 | 0.956 | 9.608 | 0.060 |
| Higher KIAA0125 expression§ | 2.300 | 1.569 | 3.371 | <0.001 | 2.188 | 1.317 | 3.636 | 0.003 |
p values < .05 are considered statistically significant
Abbreviations: HR, hazard ratios; CI, confidence interval
*As continuous variable
†Unfavorable cytogenetics versus others. The classification of favorable, intermediate and unfavorable cytogenetics is based on the refined Medical Research Council (MRC) classification [27]. Favorable: t(15;17)(q22;q21), t(8;21)(q22;q22), and inv.(16)(p13q22)/t(16;16)(p13;q22); unfavorable: abn(3q) (excluding t(3;5)(q25;q34)), inv.(3)(q21q26)/t(3;3)(q21;q26), add(5q)/del(5q), −5, −7, add(7q)/del(7q), t(6;11)(q27;q23), t(10;11)(p1113;q23), other t(11q23) (excluding t(9;11)(p21 ~ 22;q23) and t(11;19)(q23;p13)), t(9;22)(q34;q11), −17, and abn(17p); and intermediate: entities not classified as favorable or adverse. Seven patients without chromosome data were not included in the analysis
‡NPM1+/FLT3-ITD- versus other subtypes
§High vs. low expression of KIAA0125